FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: A prospective study

Massimiliano Berretta, Alessandro Cappellani, Francesco Fiorica, Guglielmo Nasti, Sergio Frustaci, Rossella Fisichella, Alessandra Bearz, Renato Talamini, Arben Lleshi, Rosa Tambaro, Alessandro Cocciolo, Maurizio Ristagno, Antonio Bolognese, Francesco Basile, Nereo Meneguzzo, Salvatore Berretta, Umberto Tirelli

Research output: Contribution to journalArticle

Abstract

Elderly patients constitute a subpopulation with special characteristics that differ from those of the general population and have been under-represented in clinical trials. We, prospectively, analyzed the toxicity and efficacy of the original FOLFOX4-regimen in the treatment of elderly patients affected by metastatic (m) colorectal cancer (CRC). Thirty-six consecutive patients aged 67-82 years (median age 72 years), 22 males and 14 females, with mCRC and measurable disease, were enrolled in the study. The primary site of metastases was the liver (36.1% of patients). The median ECOG Performance Status (PS) was 1. The main hematological and extra-hematological (grade 3 or 4) toxicities were neutropenia (38.9%) and neurological (13.9%), respectively. A total of 36 patients, aged 67-82 years were included. Twenty-two and 14 patients were male and female, respectively. The median age was 72 years (range 67-82). The primary site of metastases was the liver (36.1% of patients). The median ECOG Performance Status (PS) was 1. The overall response rate (ORR) was 44.4% and similar to original study. Median progression-free survival (PFS) was 7.5 months and median overall survival (OS) was 16 months. The main hematological and extra-hematological (grade 3 or 4) toxicities were neutropenia (38.9%) and neurological (13.9%), respectively. Tolerability, however, was manageable and no toxic death occurred. FOLFOX4-regimen maintains its efficacy, and safety ratio in elderly patients with mCRC and good performance status. It would be considered the treatment of choice in the treatment of this particular setting of patients.

Original languageEnglish
Pages (from-to)89-93
Number of pages5
JournalArchives of Gerontology and Geriatrics
Volume52
Issue number1
DOIs
Publication statusPublished - Jan 2011

    Fingerprint

Keywords

  • Cancer therapy in elderly
  • Colorectal cancer
  • Metastatic cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology
  • Health(social science)
  • Gerontology

Cite this

Berretta, M., Cappellani, A., Fiorica, F., Nasti, G., Frustaci, S., Fisichella, R., Bearz, A., Talamini, R., Lleshi, A., Tambaro, R., Cocciolo, A., Ristagno, M., Bolognese, A., Basile, F., Meneguzzo, N., Berretta, S., & Tirelli, U. (2011). FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: A prospective study. Archives of Gerontology and Geriatrics, 52(1), 89-93. https://doi.org/10.1016/j.archger.2010.02.006